Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review

AlMukdad Sawsan; Elewa Hazem; Al-Badriyeh Daoud

首页> 外文期刊>Journal of cardiovascular pharmacology and therapeutics >Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review

【24h】

Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review

机译：CYP2C19基因型引导抗血小板治疗的经济评价与急性冠状动脉综合征患者普遍使用抗血糖素：系统审查

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and Objectives:

机译：背景和目标：

著录项

来源
《Journal of cardiovascular pharmacology and therapeutics》 |2020年第3期|共11页
作者
AlMukdad Sawsan; Elewa Hazem; Al-Badriyeh Daoud;
展开▼
作者单位

Qatar Univ Coll Pharm QU Hlth Doha Qatar;

Qatar Univ Coll Pharm QU Hlth Doha Qatar;

Qatar Univ Coll Pharm QU Hlth Doha Qatar;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类产科学;
关键词
clopidogrel; prasugrel; ticagrelor; cost-effectiveness; percutaneous coronary intervention;

机译：氯吡格雷;普拉布雷;Ticagrelor;成本效益;经皮冠状动脉介入;

相似文献

外文文献
中文文献
专利

1. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review [J] . AlMukdad Sawsan, Elewa Hazem, Al-Badriyeh Daoud Journal of cardiovascular pharmacology and therapeutics . 2020,第3期

机译：CYP2C19基因型引导抗血小板治疗的经济评价与急性冠状动脉综合征患者普遍使用抗血糖素：系统审查
2. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes ( SMART-DATE) prospective multicenter randomized trial [J] . Lee Joo Myung, Cho Deok-Kyu, Hahn Joo-Yong, The American heart journal . 2016,第期

机译：急性冠状动脉综合征患者经皮冠状动脉干预后6个月持续时间持续时间：理论与设计急性冠状动脉患者急性冠状动脉经皮冠状动脉介入后6个月持续时间急性血管成形术研究团队 - 安全性综合征（智能日期）预期多中心随机试验
3. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients [J] . Lee John Andrew, Lee Craig R., Reed Brent N., Pharmacogenomics . 2015,第4期

机译：CYP2C19基因型指导的抗血小板治疗算法在高危冠心病患者中的实施和评估
4. Antiplatelet Treatment in Acute Coronary Syndromes Where Do We Stand? [C] . M. Keltai International Congress on Coronary Artery Disease . 2007

机译：抗血小板治疗在急性冠状动脉综合征中我们站在哪里？
5. The Comparative Effectiveness, Safety, and Cost of Oral P2Y12 Antiplatelet Agents Following Acute Coronary Syndromes [D] . Belviso, Nicholas J. 2020

机译：口服P2Y12抗血小板药物的比较有效性，安全性和成本急性冠状动脉综合征
6. Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China [O] . Yi Zhang, Xiu-Jin Shi, Wen-Xing Peng, 2020

机译：经皮冠状动脉干预后实施CYP2C19基因型引导抗血小板治疗抗血小板治疗对急性冠状动脉综合征患者P2Y12抑制剂选择及临床结果的影响：中国的真实研究
7. PRM57 Cost-Effectiveness Evaluation Of Genotype-Guided Antiplatelet Therapy Versus Universal New Antiplatelet Therapy In Patients With Acute Coronary Syndrome [O] . Jiang M., You J. 2015

机译：PRM57基因型引导的抗血小板治疗与急性冠状动脉综合征患者的通用新抗血小板治疗的成本-效果评价

Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review

摘要

著录项

相似文献

相关主题

期刊订阅